Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2020-08-04 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - HMD 5 pages 27.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Heramed Limited. It details the number of securities to be issued, the issue price, the proposed issue date, and other related information such as fees and approvals. The content focuses on the company's capital raising activity through a placement or other type of issue. There are no financial statements or comprehensive financial performance data included, and the document is not a report but an announcement of a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2020-08-04 English
Cleansing Notice 1 page 87.0KB
Capital/Financing Update Classification · 100% confidence The document is a notification pursuant to paragraph 708A(5)(e) of the Corporations Act 2001, indicating the company will issue fully paid ordinary shares to sophisticated investors without disclosure under Part 6D.2 of the Act. It is a formal announcement about a share issue event, specifically notifying the market about the capital raising under a specific legal exemption. The document is short (1761 characters) and does not contain financial statements or detailed financial data. It is not a full report but a regulatory announcement about a capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2020-08-04 English
Change of Director's Interest Notice 3 pages 134.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the change (on-market purchase), and value consideration. This is a clear report of personal share transactions by a company director. There is no indication of financial results, management discussion, or other report types. The document matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is the actual notice, not an announcement or certification. Therefore, the correct classification is DIRS.
2020-08-02 English
Updated Quarterly Activities Report 5 pages 165.5KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 3 August 2020 providing a quarterly update on HeraMED Limited's business activities, including clinical trials, collaborations, commercialisation strategy, and a capital raise. It covers the three months ending 30 June 2020 (Q2 FY20), with detailed operational and financial highlights such as cash balance, expenditure, and payments to related parties. The content is typical of a quarterly business update with financial and operational data but does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). It is longer than a brief announcement but structured as a quarterly business update. The presence of financial figures and operational progress for a quarter strongly indicates it is an Interim / Quarterly Report rather than a simple announcement or earnings release. Therefore, the document fits best under the category Interim / Quarterly Report (IR). Q2 2020
2020-08-02 English
Quarterly Activities & Cashflow Report 8 pages 293.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 July 2020 providing a detailed update on HeraMED Limited's Q2 FY20 activities, including clinical collaborations, commercialisation strategy, capital raising, and a quarterly cash flow report (Appendix 4C) as required by ASX Listing Rule 4.7B. The content includes operational highlights, strategic agreements, clinical study updates, and a financial overview with cash flow statements for the quarter ended 30 June 2020. The presence of the Appendix 4C quarterly cash flow report and the focus on quarterly operational and financial updates indicate this is an Interim / Quarterly Report. The document is comprehensive (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2020
2020-07-28 English
Study Commenced & Recruitment Initiated - Joondalup Campus 2 pages 90.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 July 2020, providing an update on the commencement and progress of a clinical study at Joondalup Health Campus by HeraMED Limited. It discusses recruitment status, study steps, and expected outcomes but does not contain financial data, regulatory filings, or detailed financial reports. It is a progress update on a clinical study rather than a financial report, management change, or regulatory filing. The document is relatively short (4907 characters) and serves as a company announcement about operational progress. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements that do not fit other categories.
2020-07-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.